Specialty Pharmacy

Top news of the day from across the health care landscape.

In a real-world setting, long-term outcomes were more favorable following early intensive therapy when compared with first-line moderate-efficacy diseased modifying therapy.

A 10 mg twice daily dose of tofacitinib (Xeljanz, Xeljanz XR, Pfizer) used in patients with rheumatoid arthritis increased the risk of blood clots in the lungs and death in a safety clinical trial.

In order for a substantial decrease of HIV infections in the United States, there needs to be a rapid expansion of prevention and treatment for individuals at risk.

The trial aimed to evaluate the survival rate of patients with metastatic hormone-sensitive prostate cancer who were treated with the combination of enzalutamide and androgen deprivation therapy.

A recent study identified genetic changes in e-cigarette users similar to those seen in cigarette smokers.

Top news of the day from across the health care landscape.

This study demonstrates the significance and efficacy of breast cancer screenings for prevention and early intervention.

The FDA approved trifluridine/tipiracil (Lonsurf, Taiho Oncology), also known as TAS-102, as a treatment for certain adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma.

The combination of Opdivo and low-dose Yervoy was compared with sunitinib for a 30-month follow-up.

Study adds to the ongoing research on immunotherapy and its potential as a viable treatment for patients with cancer.

New research supports the use of direct-acting antiviral therapy for all individuals with chronic hepatitis C infection.

Ron Lanton III, Esq., executive director and senior counsel for Frier Levitt Government Affairs, explains the most effective way to facilitate DIR fee reform on a state and federal level.

Study explores the efficiency and accuracy of aspirin in colorectal cancer prevention.

Study highlights the importance of managing depression and anxiety to mitigate the effect on the cognitive function of patients with multiple sclerosis.

Top news of the week from Specialty Pharmacy Times.

The T cell marker could help lead the improved treatment for HIV and cancer patients.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

Polypharmacy can contribute to a higher risk of health problems, such as drug interactions and adverse effects.

Translational study of breast cancer therapy sought to ‘take research from bench to bedside.’

Top news of the day from across the health care landscape.

Longitudinal study of direct-acting antivirals for hepatitis C virus infection finds that treatment provides clinical benefit beyond virologic response, reducing risk for both all-cause mortality and for liver cancer.

Seladelpar would be indicated for patients with primary biliary cholangitis in combination with ursodeoxycholic acid (UDCA) who have an inadequate response to UDCA or as a monotherapy in adults unable to tolerate UDCA.

Top news of the day across the health care landscape.

Researchers at Brigham and Women’s Hospital set out to evaluate the effects of switching insulins in those with type 2 diabetes.

The New Drug Application for upadacitinib is supported by data from the phase 3 SELECT trial program evaluating patients with moderate-to-severe rheumatoid arthritis.

Turoctocog alfa pegol, also known as N8-GP (Esperoct, Novo Nordisk), is indicated for adults and children with hemophilia A.

Pembrolizumab (Keytruda, Merck) is the first anti-PD-1 therapy approved in the adjuvant setting across patients with stage 3 melanoma.

Pembrolizumab (Keytruda) plus axitinib (Inlyta) was evaluated in a clinical trial of patients with clear-cell metastatic renal cell carcinoma.

Blocking the interaction between interleukin-33 and regulatory T cells may serve as a new therapeutic target for cancers associated with chronic inflammatory diseases.